Compare ISSC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISSC | PRLD |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 346.5M |
| IPO Year | 2000 | 2020 |
| Metric | ISSC | PRLD |
|---|---|---|
| Price | $18.10 | $4.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $18.25 | $5.67 |
| AVG Volume (30 Days) | 433.0K | ★ 489.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 23.21 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $7.95 | $320.10 |
| Revenue Next Year | $6.82 | $100.00 |
| P/E Ratio | $43.63 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $8.13 | $0.75 |
| 52 Week High | $30.98 | $5.54 |
| Indicator | ISSC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 60.83 |
| Support Level | $17.57 | $3.92 |
| Resistance Level | $19.92 | $5.43 |
| Average True Range (ATR) | 1.12 | 0.35 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 59.63 | 92.78 |
Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.